Pal-AHK vs Leuprolide
Side-by-side comparison of key properties, dosing, and research.
Skin & CosmeticAnti-Aging & Longevity
Pal-AHKSexual Health & Libido
Leuprolide- Summary
- Pal-AHK is the palmitoylated form of the AHK-Cu copper tripeptide, created by attaching a palmitic acid chain to enhance skin penetration and lipid bilayer affinity. The palmitoyl modification significantly improves dermal bioavailability compared to unmodified AHK, making it particularly effective in anti-aging and hair growth formulations.
- Leuprolide is a synthetic GnRH superagonist that, with continuous administration, paradoxically suppresses LH and FSH through receptor desensitization — the opposite effect of pulsatile GnRH. Used medically for prostate cancer, endometriosis, and precocious puberty. In men's health, short-duration use for PCT and testosterone suppression rebound.
- Half-Life
- Extended (lipid depot effect in stratum corneum)
- ~3 hours (SC/IM), but depot formulations last 1–12 months
- Admin Route
- Topical
- SubQ, IM
- Research
- —
- —
- Typical Dose
- 0.01–0.05% in formulation
- 7.5 mg monthly, 22.5 mg 3-monthly, or 45 mg 6-monthly
- Frequency
- Once or twice daily
- Per depot schedule
- Key Benefits
- Enhanced skin penetration vs. unmodified AHK-Cu
- Stimulates dermal collagen and elastin production
- Promotes hair follicle anagen phase
- Antioxidant and wound healing activity
- Firming and plumping effect on aging skin
- Improved bioavailability via lipid bilayer incorporation
- Medical: reduces testosterone in prostate cancer
- Medical: suppresses estrogen in endometriosis and uterine fibroids
- Medical: delays precocious puberty
- Research: testosterone rebound effect after short course
- Transgender care: hormone suppression in adolescents
- Research: hormonal re-sensitization protocols
- Side Effects
- Generally well-tolerated
- Mild irritation at high concentrations in sensitive skin
- Possible comedogenicity at very high palmitate concentrations (formulation-dependent)
- Hot flashes (with testosterone suppression)
- Decreased libido and erectile dysfunction
- Initial testosterone flare (first 1–2 weeks)
- Bone density loss with long-term use
- +3 more
- Stacks With
- —
- —